Venus Remedies

{
  "main_header": {
    "sid": 568580,
    "name": "Venus Remedies",
    "stock_name": "Venus Remedies",
    "full_name": "Venus Remedies Ltd",
    "name_url": "stocks-analysis/venus-remedies",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "787.15",
    "chg": -25.7,
    "chgp": "-3.16%",
    "dir": -1,
    "prev_price": "812.85",
    "mcapval": "1,096.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 526953,
    "symbol": "VENUSREM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE411B01019",
    "curr_date": "Feb 02",
    "curr_time": "",
    "bse_nse_vol": "24.52 k",
    "exc_status": "Active",
    "traded_date": "Feb 02, 2026",
    "traded_date_str": "2026 02 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/venus-remedies-568580-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "MN",
      "url": "https://www.marketsmojo.com/mojopro/strategy/2",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/venus-remedies-568580-1&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Venus Remedies Ltd Hits New 52-Week High at Rs.872.8",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-hits-new-52-week-high-at-rs8728-3815970",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_priceRelatedfactors_3815970.png",
        "date": "2026-02-02 09:48:58",
        "description": "Venus Remedies Ltd has reached a significant milestone by hitting a new 52-week and all-time high of Rs.872.8, marking a remarkable surge in its stock price amid strong market momentum and robust financial performance."
      },
      {
        "title": "Venus Remedies Ltd Stock Hits Record High of Rs.872.8 on 2 Feb 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-stock-hits-record-high-of-rs8728-on-2-feb-2026-3815918",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_priceRelatedfactors_3815918.png",
        "date": "2026-02-02 09:33:32",
        "description": "Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.872.8 on 2 Feb 2026, underscoring its robust performance and sustained growth trajectory in a competitive market environment."
      },
      {
        "title": "Venus Remedies Ltd Downgraded to Buy Amid Valuation and Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venus-remedies-ltd-downgraded-to-buy-amid-valuation-and-technical-shifts-3815784",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_mojoScore_3815784.png",
        "date": "2026-02-02 08:36:53",
        "description": "Venus Remedies Ltd has seen its investment rating downgraded from Strong Buy to Buy as of 1 February 2026, reflecting a recalibration of its valuation and technical outlook despite robust financial performance and quality metrics. The revised Mojo Score now stands at 74.0, signalling a solid but more cautious stance on the stock within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Venus Remedies Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-valuation-shifts-signal-changing-market-sentiment-3813655",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenusRemediesLt_valuationdot_3813655.png",
        "date": "2026-02-01 08:02:56",
        "description": "Venus Remedies Ltd has recently experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Venus Remedies Ltd Gains 12.63%: 4 Key Factors Driving the Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-gains-1263-4-key-factors-driving-the-surge-3813113",
        "imagepath": "",
        "date": "2026-01-31 17:01:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Jan:</strong> Stock opens strong at Rs.750.20 (+3.28%)</p>\n                    <p><strong>29 Jan:</strong> Q3 FY26 results reveal profit surge; upgraded to Strong Buy; bullish technical momentum</p>\n                    <p><strong>30 Jan:</strong> Hits upper circuit at Rs.818.00 (+4.67%) on robust buying</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.726.40</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.818.15</div><div class=\"stat-change positive\">+12.63%</div></div>\n         ..."
      },
      {
        "title": "Are Venus Remedies Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-venus-remedies-ltd-latest-results-good-or-bad-3811909",
        "imagepath": "",
        "date": "2026-01-30 19:24:15",
        "description": "Venus Remedies Ltd's latest financial results reveal a complex operational landscape characterized by notable profit growth alongside significant margin volatility. In Q2 FY26, the company reported net sales of ₹192.75 crores, reflecting a quarter-on-quarter increase of 40.51% and a year-on-year growth of 13.32%. This growth trajectory indicates the company's ability to capture market share within the competitive injectables segment. However, the operating margin, while improving to 16.06% from 11.21% in the previous quarter, remains below the 18.34% peak achieved in Q4 FY25, highlighting ongoing challenges in margin consistency.\n\nThe net profit for Q2 FY26 stood at ₹20.13 crores, marking a substantial quarter-on-quarter increase of 109.69% and an impressive year-on-year growth of 473.50%. Despite these positive figures, the pronounced volatility in profitability metrics raises questions about the sustainab..."
      },
      {
        "title": "Venus Remedies Ltd Surges to Upper Circuit on Robust Buying Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venus-remedies-ltd-surges-to-upper-circuit-on-robust-buying-momentum-3810916",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/VenusRemediesLt_stocks_hitting_upper_circuit_3810916.png",
        "date": "2026-01-30 10:00:22",
        "description": "Venus Remedies Ltd surged to hit its upper circuit limit on 30 Jan 2026, propelled by strong buying interest and positive market sentiment. The pharmaceutical company’s shares closed at ₹818.00, marking a 4.67% gain on the day and edging closer to its 52-week high, signalling renewed investor confidence in its growth prospects."
      },
      {
        "title": "Venus Remedies Q3 FY26: Stellar Profit Surge Masks Underlying Margin Volatility",
        "link": "https://www.marketsmojo.com/news/result-analysis/venus-remedies-q3-fy26-stellar-profit-surge-masks-underlying-margin-volatility-3810181",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/VenusRemedies_quaterlyResult_3810181.png",
        "date": "2026-01-29 21:02:13",
        "description": "Venus Remedies Ltd., the Chandigarh-based pharmaceutical company specialising in injectable formulations, delivered an impressive Q2 FY26 performance with net profit surging 109.69% quarter-on-quarter to ₹20.13 crores, whilst revenue expanded 40.51% to ₹192.75 crores. The company, commanding a market capitalisation of ₹1,025 crores, saw its shares rally 3.27% to ₹784.90 following the results announcement, extending a remarkable 170.42% gain over the past year."
      },
      {
        "title": "Venus Remedies Ltd Upgraded to Strong Buy on Robust Financials and Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venus-remedies-ltd-upgraded-to-strong-buy-on-robust-financials-and-technicals-3808880",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/VenusRemediesLt_mojoScore_3808880.png",
        "date": "2026-01-29 08:11:20",
        "description": "Venus Remedies Ltd has seen its investment rating upgraded from Buy to Strong Buy, reflecting significant improvements across quality, valuation, financial trends, and technical indicators. The pharmaceutical company’s stellar quarterly performance, combined with bullish technical signals and attractive valuation metrics, has prompted this positive reassessment by MarketsMOJO as of 28 Jan 2026."
      }
    ],
    "total": 336,
    "sid": "568580",
    "stock_news_url": "https://www.marketsmojo.com/news/venus-remedies-568580"
  },
  "announcements": [
    {
      "details": "Venus Remedies Limited has informed the Exchange regarding Disclosure of Related Party Transaction under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
      "source": "NSE",
      "caption": "Venus Remedies Limited - Other General Purpose",
      "datetime": "09-Dec-2019"
    },
    {
      "details": "Venus Remedies Limited has informed the Exchange regarding 'newspaper publication of Financial results.'.",
      "source": "NSE",
      "caption": "Venus Remedies Limited - Updates",
      "datetime": "18-Nov-2019"
    },
    {
      "details": "Venus Remedies Limited has informed the Exchange regarding Board meeting held on November 12, 2019.",
      "source": "NSE",
      "caption": "Venus Remedies Limited - Outcome of Board Meeting",
      "datetime": "13-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Venus Remedies Ltd has declared <strong>30%</strong> dividend, ex-date: 23 Sep 13",
          "dt": "2013-09-23",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Venus Remedies Ltd Hits New 52-Week High at Rs.872.8

2026-02-02 09:48:58

Venus Remedies Ltd has reached a significant milestone by hitting a new 52-week and all-time high of Rs.872.8, marking a remarkable surge in its stock price amid strong market momentum and robust financial performance.

Read full news article

Venus Remedies Ltd Stock Hits Record High of Rs.872.8 on 2 Feb 2026

2026-02-02 09:33:32

Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.872.8 on 2 Feb 2026, underscoring its robust performance and sustained growth trajectory in a competitive market environment.

Read full news article

Venus Remedies Ltd Downgraded to Buy Amid Valuation and Technical Shifts

2026-02-02 08:36:53

Venus Remedies Ltd has seen its investment rating downgraded from Strong Buy to Buy as of 1 February 2026, reflecting a recalibration of its valuation and technical outlook despite robust financial performance and quality metrics. The revised Mojo Score now stands at 74.0, signalling a solid but more cautious stance on the stock within the Pharmaceuticals & Biotechnology sector.

Read full news article

Venus Remedies Ltd Valuation Shifts Signal Changing Market Sentiment

2026-02-01 08:02:56

Venus Remedies Ltd has recently experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

Venus Remedies Ltd Gains 12.63%: 4 Key Factors Driving the Surge

2026-01-31 17:01:22

Key Events This Week

27 Jan: Stock opens strong at Rs.750.20 (+3.28%)

29 Jan: Q3 FY26 results reveal profit surge; upgraded to Strong Buy; bullish technical momentum

30 Jan: Hits upper circuit at Rs.818.00 (+4.67%) on robust buying

Week Open

Rs.726.40

Week Close

Rs.818.15

+12.63%

...

Read full news article

Are Venus Remedies Ltd latest results good or bad?

2026-01-30 19:24:15

Venus Remedies Ltd's latest financial results reveal a complex operational landscape characterized by notable profit growth alongside significant margin volatility. In Q2 FY26, the company reported net sales of ₹192.75 crores, reflecting a quarter-on-quarter increase of 40.51% and a year-on-year growth of 13.32%. This growth trajectory indicates the company's ability to capture market share within the competitive injectables segment. However, the operating margin, while improving to 16.06% from 11.21% in the previous quarter, remains below the 18.34% peak achieved in Q4 FY25, highlighting ongoing challenges in margin consistency. The net profit for Q2 FY26 stood at ₹20.13 crores, marking a substantial quarter-on-quarter increase of 109.69% and an impressive year-on-year growth of 473.50%. Despite these positive figures, the pronounced volatility in profitability metrics raises questions about the sustainab...

Read full news article

Venus Remedies Ltd Surges to Upper Circuit on Robust Buying Momentum

2026-01-30 10:00:22

Venus Remedies Ltd surged to hit its upper circuit limit on 30 Jan 2026, propelled by strong buying interest and positive market sentiment. The pharmaceutical company’s shares closed at ₹818.00, marking a 4.67% gain on the day and edging closer to its 52-week high, signalling renewed investor confidence in its growth prospects.

Read full news article

Venus Remedies Q3 FY26: Stellar Profit Surge Masks Underlying Margin Volatility

2026-01-29 21:02:13

Venus Remedies Ltd., the Chandigarh-based pharmaceutical company specialising in injectable formulations, delivered an impressive Q2 FY26 performance with net profit surging 109.69% quarter-on-quarter to ₹20.13 crores, whilst revenue expanded 40.51% to ₹192.75 crores. The company, commanding a market capitalisation of ₹1,025 crores, saw its shares rally 3.27% to ₹784.90 following the results announcement, extending a remarkable 170.42% gain over the past year.

Read full news article

Venus Remedies Ltd Upgraded to Strong Buy on Robust Financials and Technicals

2026-01-29 08:11:20

Venus Remedies Ltd has seen its investment rating upgraded from Buy to Strong Buy, reflecting significant improvements across quality, valuation, financial trends, and technical indicators. The pharmaceutical company’s stellar quarterly performance, combined with bullish technical signals and attractive valuation metrics, has prompted this positive reassessment by MarketsMOJO as of 28 Jan 2026.

Read full news article

View All News